ArticleFrontiers in oncology2026
Impact of total gastrectomy plus perioperative PD-1 inhibitors on survival in locally advanced gastric cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognosis for locally advanced gastric cancer (LAGC) remains suboptimal with standard perioperative chemotherapy. Integrating PD-1 inhibitors into this regimen is a promising strategy requiring further validation. Objective: To evaluate the efficacy and safety of total gastrectomy plus perioperative PD-1 inhibitor (Sintilimab) in the management of locally advanced gastric cancer (LAGC). Methods: In this retrospective cohort study, 200 patients with LAGC undergoing total gastrectomy (January 2021 - November 2022) were categorized based on treatment received into an experimental group (perioperative sintilimab + XELOX, n=100) and a control group (perioperative XELOX alone, n=100). Results: The experimental group demonstrated the markedly higher rates of R0 resection rate (97%: 90%, Conclusion: Total gastrectomy combined with perioperative sintilimab +XELOX regimen for LAGC significantly improves radical surgery, pathological response rate and long-term survival, with a manageable safety profile, offering a potentially effective treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.